Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Fanchamps, A.
1978.
Ergot Alkaloids and Related Compounds.
p.
567.
Hollister, Leo E.
1978.
Stimulants.
p.
389.
Miller, William R.
and
Hester, Reid K.
1986.
Treating Addictive Behaviors.
p.
121.
Dyck, Erika
2006.
‘Hitting Highs at Rock Bottom’: LSD Treatment for Alcoholism, 1950–1970.
Social History of Medicine,
Vol. 19,
Issue. 2,
p.
313.
Krebs, Teri S
and
Johansen, Pål-Ørjan
2012.
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.
Journal of Psychopharmacology,
Vol. 26,
Issue. 7,
p.
994.
de Veen, Bas T.H.
Schellekens, Arnt F.A.
Verheij, Michel M.M.
and
Homberg, Judith R.
2017.
Psilocybin for treating substance use disorders?.
Expert Review of Neurotherapeutics,
Vol. 17,
Issue. 2,
p.
203.
Fuentes, Juan José
Fonseca, Francina
Elices, Matilde
Farré, Magí
and
Torrens, Marta
2020.
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials.
Frontiers in Psychiatry,
Vol. 10,
Issue. ,
Inserra, Antonio
De Gregorio, Danilo
Gobbi, Gabriella
and
Nader, Michael
2021.
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.
Pharmacological Reviews,
Vol. 73,
Issue. 1,
p.
202.
Andersen, Kristoffer A. A.
Carhart‐Harris, Robin
Nutt, David J.
and
Erritzoe, David
2021.
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies.
Acta Psychiatrica Scandinavica,
Vol. 143,
Issue. 2,
p.
101.
Mendes, Fúlvio Rieli
Costa, Cristiane dos Santos
Wiltenburg, Victor Distefano
Morales-Lima, Gabriela
Fernandes, João Ariel Bonar
and
Filev, Renato
2022.
Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research.
Addiction Neuroscience,
Vol. 3,
Issue. ,
p.
100025.
da Costa, Sabrina Correa
Oesterle, Tyler
Rummans, Teresa A.
Richelson, Elliot
and
Gold, Mark
2022.
Psychedelic drugs for psychiatric disorders.
Journal of the Neurological Sciences,
Vol. 440,
Issue. ,
p.
120332.
Hilal, Fahd François
Jeanblanc, Jerome
Deschamps, Chloé
Naassila, Mickael
Pierrefiche, Olivier
and
Ben Hamida, Sami
2024.
Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies.
Journal of Neural Transmission,
Vol. 131,
Issue. 5,
p.
525.
Marinho, Eduardo A.V.
Serra, Yasmim A.
Oliveira-Lima, Alexandre J.
Marcourakis, Tânia
and
Berro, Laís F.
2024.
Wong, Stanley
Yu, An Yi
Fabiano, Nicholas
Finkelstein, Ofer
Pasricha, Aryan
Jones, Brett D.M.
Rosenblat, Joshua D.
Blumberger, Daniel M.
Mulsant, Benoit H.
and
Husain, M. Ishrat
2024.
Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.
Journal of Psychoactive Drugs,
Vol. 56,
Issue. 4,
p.
513.
Walsh, Claire A.
Gorfinkel, Lauren
Shmulewitz, Dvora
Stohl, Malki
and
Hasin, Deborah S.
2024.
Use of Lysergic Acid Diethylamide by Major Depression Status.
JAMA Psychiatry,
Vol. 81,
Issue. 1,
p.
89.
eLetters
No eLetters have been published for this article.